Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Sarcoma 3Sarcoma, Ewing 2Insulin-Like Growth Factor I, Resistance To 2Carcinoma, Non-Small-Cell Lung 2Carcinoid Tumor 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Jaundice 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

ganitumab 2conatumumab 1cixutumumab 1Paclitaxel 1Lapatinib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Insulin-Like Growth Factor I, Resistance To × ganitumab × Clear all
NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NantCell, Inc.

Phase 1/2 Completed
138 enrolled 19 charts
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡